GSK paid $55 million upfront to China's SiranBio for SA030, a phase 1-stage oligonucleotide therapy with up to $1 billion in milestone payments and tiered royalties
SA030 targets activin receptor-like kinase 7 (ALK7), a protein believed to reduce abdominal fat while preserving lean mass
The drug aims to improve insulin sensitivity, blood lipid profile, and reduce fat cell-driven inflammation through adipocyte-directed delivery
SiranBio is completing a phase 1 trial testing tolerability and pharmacokinetics in patients with overweight or obesity before handing the drug to GSK
SA030 represents a distinct mechanism from GLP-1 drugs, potentially allowing combination regimens with other weight-loss or diabetes treatments
GSK's strategy focuses on cardiometabolic diseases associated with obesity rather than direct weight-loss competition